Loading…
ProMIS Neurosciences, Inc. is projected to rise to $10.92 by 2027, a +4% move from its current price of $10.48. PMN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.11 | $10.47 | $10.85 | -0.02% |
| May 30 | $9.96 | $10.47 | $11.00 | -0.05% |
| May 31 | $9.85 | $10.47 | $11.12 | -0.07% |
| Jun 1 | $9.76 | $10.47 | $11.23 | -0.09% |
| Jun 2 | $9.67 | $10.46 | $11.32 | -0.11% |
| Jun 3 | $9.60 | $10.46 | $11.40 | -0.14% |
| Jun 4 | $9.53 | $10.46 | $11.48 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.53 | $10.46 | $11.48 | -0.16% |
| Week 2 | $9.16 | $10.44 | $11.91 | -0.32% |
| Week 3 | $8.87 | $10.42 | $12.25 | -0.48% |
| Week 4 | $8.64 | $10.41 | $12.53 | -0.64% |
| Week 5 | $8.44 | $10.39 | $12.79 | -0.80% |
| Week 6 | $8.26 | $10.37 | $13.03 | -0.96% |
| Week 7 | $8.10 | $10.36 | $13.25 | -1.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ProMIS Neurosciences, Inc. is a healthcare company focused on discovering and developing antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. Its proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
Lead product candidates include PMN310, a monoclonal antibody for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a monoclonal antibody targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences is headquartered in Toronto, Canada.
PMN is the stock of ProMIS Neurosciences, Inc. (PMN) in the Healthcare sector. It currently trades at $10.98 per share with a market capitalization of $98.47M and is ranked 4238 by market value.
The asset sits in the Healthcare category, with a multi-year forecast showing upside potential across several years. For 2026 the avg price is $10.98 with a min of $7.14 and a max of $14.62, and the forecast includes a 0 ROI for that year. Looking further out, 2030 shows an avg of $13.42 and a max of $20.77 with a 22.2 ROI, and 2050 shows an avg of $59.81 with a max of $122.98 and a 444.7 ROI.
The forecast also marks sentiment as BULLISH in later years, reflecting expectations of substantial appreciation from the current level.
A major floor 22.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.2% below — buyers have tended to step in here.
The nearest ceiling, 17.4% above — a clean break opens room to run.
A major ceiling 136.7% above — clearing it would confirm fresh momentum.
Key PMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.65 | Sell | $10.58 | Sell |
| MA 10 | $10.59 | Sell | $10.61 | Sell |
| MA 20 | $10.65 | Sell | $10.83 | Sell |
| MA 50 | $12.26 | Sell | $12.02 | Sell |
| MA 100 | $13.44 | Sell | $12.59 | Sell |
| MA 200 | $12.08 | Sell | $13.50 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.74 | Neutral |
| Stoch RSI (14) | 69.49 | Neutral |
| CCI (20) | -38.92 | Neutral |
| Williams %R (14) | -43.48 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 6.61 | Buy |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 56.52 | Neutral |
| TRIX (15) | -0.76 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 48.51 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 10.67 | Sell |
| ADX (14) | 21.62 | Sell |
| ATR (14) | 0.30 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 50, with the 30-day moving average lying around the current level: SMA50 at $12.61 and SMA200 at $12.11. The stock’s near-term technicals show support at $9.83 and resistance at $12.92. The 30-day price range runs from a low of $8.69 to a high of $13.87, indicating limited momentum in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.14 | $10.48 | $13.94 | 0% | Neutral | |
| $8.42 | $10.92 | $15.13 | +4% | Neutral | |
| $7.71 | $10.37 | $15.02 | -1% | Neutral | |
| $8.37 | $11.61 | $17.41 | +11% | Neutral | |
| $8.83 | $12.57 | $19.41 | +20% | Bullish | |
| $9.85 | $14.38 | $22.77 | +37% | Bullish | |
| $11.76 | $17.58 | $28.48 | +68% | Bullish | |
| $11.33 | $17.33 | $28.65 | +65% | Bullish | |
| $10.66 | $16.64 | $28.04 | +59% | Bullish | |
| $11.16 | $17.79 | $30.50 | +70% | Bullish | |
| $14.70 | $25.76 | $47.51 | +146% | Bullish | |
| $26.31 | $54.64 | $111.90 | +422% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.14 | $10.48 | $12.35 | +0.00% |
| June 2026 | $8.69 | $10.27 | $12.48 | -1.93% |
| July 2026 | $8.59 | $10.26 | $12.67 | -0.14% |
| August 2026 | $8.91 | $10.73 | $13.43 | +4.61% |
| September 2026 | $8.93 | $10.83 | $13.70 | +0.92% |
| October 2026 | $8.60 | $10.51 | $13.42 | -2.96% |
| November 2026 | $8.60 | $10.57 | $13.61 | +0.54% |
| December 2026 | $8.69 | $10.73 | $13.94 | +1.59% |
Click any year to see its month-by-month PMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ProMIS Neurosciences, Inc.'s 2026 outlook centres on $10.48, within a $7.14 to $13.94 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PMN could reach as high as $15.13, with a base case around $10.92 and support toward $8.42 — roughly +4% from $10.48. A consolidation phase looks the most probable path here.
Expect PMN to range from $7.71 to $15.02 through 2028. The $10.37 average target implies a -1% move from current prices. That is -5% versus the projected 2027 average. Price action looks broadly range-bound.
The PMN price prediction for 2029 points to an average of $11.61 (low $8.37, high $17.41) — a potential gain of +11% on today's $10.48. A consolidation phase looks the most probable path here.
In 2030, PMN is projected to trade between $8.83 and $19.41, averaging $12.57 — a potential gain of +20% from today's $10.48. That is up +8% on the projected 2029 average. Momentum favours further upside here.
ProMIS Neurosciences, Inc.'s 2031 outlook centres on $14.38, within a $9.85 to $22.77 range. That is up +14% on the projected 2030 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PMN could reach as high as $28.48, with a base case around $17.58 and support toward $11.76 — roughly +68% from $10.48. Momentum favours further upside here.
Expect PMN to range from $11.33 to $28.65 through 2033. The $17.33 average target implies a +65% move from current prices. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The PMN price prediction for 2034 points to an average of $16.64 (low $10.66, high $28.04) — a potential gain of +59% on today's $10.48. Momentum favours further upside here.
In 2035, PMN is projected to trade between $11.16 and $30.50, averaging $17.79 — a potential gain of +70% from today's $10.48. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
ProMIS Neurosciences, Inc.'s 2040 outlook centres on $25.76, within a $14.70 to $47.51 range. That is up +45% on the projected 2035 average. That marks a +146% change versus current levels. Momentum favours further upside here.
By 2050, PMN could reach as high as $111.90, with a base case around $54.64 and support toward $26.31 — roughly +422% from $10.48. Buyers look set to stay in control over this stretch.
Investing $1,000 in PMN today (≈ 95.465394 PMN) could be worth
$5,216.25
+$4,216.25 (+422%) by 2050 · US Dollar
Based on the average projected PMN price of $54.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMNwould be worth at today's price.
$1,000 invested in PMN on May 27, 2025 (≈ 75.471698 PMN) would be worth
$790.57
-$209.43 (-20.9%) today · 0.79× · US Dollar
Based on a PMN entry price of $13.25 vs. today's $10.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.6 | $988.21 | -1.2% |
| 1 month ago | $11.1 | $943.69 | -5.6% |
| 3 months ago | $20.86 | $502.16 | -49.8% |
| 6 months ago | $6.76 | $1,549.56 | +55.0% |
| 1 year ago | $13.25 | $790.57 | -20.9% |
| All time (5.0y) ago | $270 | $38.8 | -96.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMN forecast.
Our base-case forecast reaches $21.00 around 2040.
Implied market cap at $21.00: $188.32M
The multi-year forecast points to a bullish trajectory beginning in the 2030s, with rising average prices and meaningful upside. In 2030 the avg is $13.42 and the max is $20.77 with a min of $9.39, and the ROI is 22.2. By 2040 the avg reaches $28.26 with a max of $52.30 and a min of $16.05, and the ROI is 157.4.
By 2050 the avg is $59.81 with a max of $122.98 and a min of $28.58, with a ROI of 444.7. Sentiment shifts to BULLISH in the later years, implying stronger upside potential despite the current neutral stance. These figures illustrate substantial longer-term upside but remain estimates and involve uncertainty and risk, especially given the early-stage nature of the company’s development programs.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $13.42 with a range from $9.39 to $20.77, and a predicted ROI of 22.2. The sentiment is marked as BULLISH for that year.
Forecasts indicate a path from a NEUTRAL stance in 2026 to BULLISH sentiment in later years, with significant upside potential by 2040 and 2050 (avg prices of $28.26 and $59.81, respectively, and ROIs of 157.4 and 444.7). However, volatility and uncertainty are acknowledged, and outcomes are not guaranteed.
Yes, the forecast for 2050 shows an avg of $59.81 and a max of $122.98, with a 444.7 ROI, indicating $60 is within the projected range for that year.
The current price is $10.98 and the market cap is $98.47M.
The 30-day range is from $8.69 to $13.87.
ProMIS Neurosciences, Inc. Community Discussion
0Share your ProMIS Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.